Please assess the completion status of the following clinical trial:

Trial Title: Hib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup C Conjugate Vaccines

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects for whom the investigator believes that their parents/guardians can and will comply with the requirements of the protocol should be enrolled in the study.~* A male or female between, and including, 6 and 12 weeks of age at the time of the first vaccination.~* Written informed consent obtained from the parent or guardian of the subject.~* Free of obvious health problems as established by medical history and clinical examination before entering into the study.~* Born after a gestation period between 36 and 42 weeks.~Exclusion Criteria:~* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.~* Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs since birth.~* Planned administration/ administration of a vaccine not foreseen by the study protocol within 30 days of the first dose of vaccine(s).~* Previous vaccination against Neisseria meningitidis, Haemophilus influenzae type b, diphtheria, tetanus, pertussis, poliovirus, and/or Streptococcus pneumoniae; more than one previous dose of hepatitis B vaccine. Vaccination with hepatitis B at birth is accepted (although not mandatory). Influenza vaccination is allowed 30 days after administration of the third vaccine dose to 30 days preceding the booster dose.~* History of Neisseria meningitidis, Haemophilus influenzae type b, diphtheria, tetanus, pertussis, hepatitis B, poliovirus, Streptococcus pneumoniae and/or varicella invasive disease.~* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.~* History of allergic disease or reactions likely to be exacerbated by any component of the vaccine(s), including dry natural latex rubber, tetanus toxoid, diphtheria toxoid, neomycin, polymyxin.~* Major congenital defects or serious chronic illness.~* History of any neurologic disorders or seizures.~* Acute disease at the time of enrolment.~* Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.~* Additional specific criteria for the booster part of the study~* History of or previous vaccination against measles, mumps, rubella or varicella.~* Previous booster vaccination with Hib or meningococcal serogroup C vaccine since the last visit of the primary phase.

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 12 Weeks
- Healthy Volunteers: t

Study Arms:
- MenHibrix Group (Type: EXPERIMENTAL): Subjects primed in study 102370 with 3 doses of MenHibrix, Infanrix Penta and Prevenar vaccines and receiving a fourth dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.
- ActHIB + Meningitec Group (Type: ACTIVE_COMPARATOR): Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta, Prevenar and Meningitec vaccines and receiving a dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.
- ActHIB/PedvaxHIB Group (Type: ACTIVE_COMPARATOR): Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta and Prevenar vaccines and receiving a dose of PedvaxHIB co-administered with M-M-RII and Varivax vaccines in study 102371.

Based on this trial design, predict the completion outcome and termination type (if applicable).